Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Brain Diseases 1

Interventions

Temozolomide 2Psychiatric Rehabilitation 2Paclitaxel 2Early Intervention, Educational 2sargramostim 1regorafenib 1pentetreotide 1pembrolizumab 1pazopanib 1imetelstat 1glutathione pegylated liposomal doxorubicin 1durvalumab 1carboxyamido-triazole 1cabozantinib 1binimetinib 1aflibercept 1Trastuzumab 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy 1Quality of Life 1Positron-Emission Tomography 1Pemetrexed 1Patient Reported Outcome Measures 1PF-07284890 1Oxycodone 1Nivolumab 1NEO212 1Morphine 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × PF-07284890 × Dermatologic × Clear all
NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Pfizer

Phase 1 Terminated
65 enrolled 52 charts
CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡